General practitioners' management of symptomatic uncomplicated diverticular disease of the colon by using rifaximin, a non-adsorbable antibiotic

被引：9

作者：

De Bastiani, R. ^{[1
]}

Sanna, G. ^{[1
]}

Bertolusso, L. ^{[1
]}

Casella, G. ^{[1
]}

De Polo, M. ^{[1
]}

Zamparella, M. ^{[1
]}

Cottone, C. ^{[1
]}

Tosetti, C. ^{[1
]}

Mancuso, M. ^{[1
]}

Pirrotta, E. ^{[1
]}

Lanzarotto, L. ^{[1
]}

Napoli, L. ^{[1
]}

De Bastiani, M. ^{[1
]}

Disclafani, G. ^{[1
]}

Gambaro, P. ^{[1
]}

Scoglio, R. ^{[1
]}

Belvedere, A. ^{[1
]}

Fasulo, S. ^{[1
]}

D'Urso, M. ^{[1
]}

Benedetto, E. ^{[1
]}

Baldi, E. ^{[1
]}

Marchesan, F. ^{[1
]}

Abagnale, G. ^{[1
]}

Turnava, L. ^{[1
]}

Salome, E. ^{[1
]}

Ingravalle, F. ^{[2
]}

Tursi, A. ^{[3
]}

机构：

[1] Italian Assoc Gastroenterol Primary Care GIGA CP, Feltre, BL, Italy

[2] Tor Vergata Univ, Postgrad Sch Hyg & Prevent Med, Rome, Italy

[3] Azienda Sanit Locale Barletta Andria Trani, Terr Gastroenterol Serv, Andria, Italy

来源：

EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES | 2021年 / 25卷 / 01期

关键词：

Acute diverticulitis; Complications; Primary care; Rifaximin; Symptomatic uncomplicated diverticular disease; Treatment; QUALITY-OF-LIFE; EFFECTIVELY PREVENTS; THERAPY; BOWEL; PHARMACOLOGY; EFFICACY; POLYPS; STILL;

D O I：

10.26355/eurrev_202101_24410

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

OBJECTIVE: Symptomatic uncomplicated diverticular disease of the colon (SUDD) is generally managed by gastroenterologists rather than General Practitioners (GPs). The aim of this study was to assess the efficacy of the treatment of SUDD with rifaximin, a non-absorbable antibiotic, in a primary care setting by GPs. PATIENTS AND METHODS: This retrospective, observational study investigated the use of rifaximin at a dose of 400 mg b.i.d. for 5, 7 or 10 days monthly, up to 3 months. The symptoms were reported by the patients using a visual analogic scale (VAS) of 0-10. RESULTS: 286 SUDD patients were enrolled (44.4% of men, average age 70.92 +/- 10.98). Respectively, 15 (5.2%) patients received the treatment for 5 days, 205 (71.7%) for 7 days and 66 (23.1%) for 10 days. After three months, a significant reduction of VAS score was observed in almost all symptoms assessed: 135 (47.2%) patients reported no abdominal pain (p<0.001) and 23 (8.1%) reported no symptom. Adverse events related to the treatment were recorded in 3 (1.04%) patients, all of them mild and not requiring interruption of the treatment. Acute diverticulitis occurred in 9 (3.1%) patients, but only 2 of them [0.7% (n=2)] underwent surgery due to complicated diverticulitis. Analysis within the different treatment groups (5, 7 and 10 days) shows that rifaximin treatment is effective in reducing the severity of symptoms in almost all groups except for the constipation in the 5-day group. CONCLUSIONS: Rifaximin can be effectively used by GPs in real-life for the management of SUDD.

引用

页码：423 / 430

页数：8

共 30 条

[1] Meta-analysis: long-term therapy with rifaximin in the management of uncomplicated diverticular disease [J].

Bianchi, M. ;

Festa, V. ;

Moretti, A. ;

Ciaco, A. ;

Mangone, M. ;

Tornatore, V. ;

Dezi, A. ;

Luchetti, R. ;

De Pascalis, B. ;

Papi, C. ;

Koch, M. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 33 (08) :902-910

[2] Is generic rifaximin still a poorly absorbed antibiotic? A comparison of branded and generic formulations in healthy volunteers [J].

Blandizzi, Corrado ;

Viscomi, Giuseppe Claudio ;

Marzo, Antonio ;

Scarpignato, Carmelo .

PHARMACOLOGICAL RESEARCH, 2014, 85 :39-44

[3] Practice styles, knowledge and attitudes of general practitioners and gastroenterology specialists who treat gastroesophageal reflux disease [J].

Carter, Dan ;

Dickman, Ram .

MEDICINE, 2018, 97 (52)

[4] Quality of life in uncomplicated symptomatic diverticular disease: Is it another good reason for treatment? [J].

Comparato, Giuseppe ;

Fanigliulo, Libera ;

Aragona, Giovanni ;

Cavestro, Giulia M. ;

Cavallaro, Lucas G. ;

Leandro, Gioacchino ;

Pilotto, Alberto ;

Nervi, Giorgio ;

Soliani, Paolo ;

Sianesi, Mario ;

Franze, Angelo ;

Di Mario, Francesco .

DIGESTIVE DISEASES, 2007, 25 (03) :252-259

[5] The Management of Patients With Diverticulosis and Diverticular Disease in Primary Care An Online Survey Among Italian General Pratictioners [J].

De Bastiani, Rudi ;

Sanna, Guido ;

Fracasso, Pierluigi ;

D'Urso, Maurizio ;

Benedetto, Edoardo ;

Tursi, Antonio .

JOURNAL OF CLINICAL GASTROENTEROLOGY, 2016, 50 :S89-S92

[6] Long-term efficacy of rifaximin to manage the symptomatic uncomplicated diverticular disease of the colon [J].

Di Mario, Francesco ;

Miraglia, Chiara ;

Cambie, Ginevra ;

Violi, Alessandra ;

Nouvenne, Antonio ;

Franceschi, Marilisa ;

Brandimarte, Giovanni ;

Elisei, Walter ;

Picchio, Marcello ;

Tursi, Antonio .

JOURNAL OF INVESTIGATIVE MEDICINE, 2019, 67 (04) :767-+

[7] Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon [J].

Latella, G ;

Pimpo, MT ;

Sottili, S ;

Zippi, M ;

Viscido, A ;

Chiaramonte, M ;

Frieri, G .

INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2003, 18 (01) :55-62

[8] Diverticulosis and diverticulitis form no risk for polyps and colorectal neoplasia in 4,241 colonoscopies [J].

Meurs-Szojda, M. M. ;

Droste, J. S. Terhaar sive ;

Kuik, D. J. ;

Mulder, C. J. J. ;

Felt-Bersma, R. J. F. .

INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2008, 23 (10) :979-984

[9]

Moniuszko A, 2017, GASTROENTEROL REV, V12, P145, DOI 10.5114/pg.2017.68167

[10] Prevalence of polyps and diverticulosis of the large bowel in the Cretan population - An autopsy study [J].

Paspatis, GA ;

Papanikolaou, N ;

Zois, E ;

Michalodimitrakis, E .

INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2001, 16 (04) :257-261

← 1 2 3 →